The presence or absence of insurance coverage for trastuzumab treatment was the strongest predictor of trastuzumab therapy use in Chinese patients.
In a recent study, researchers sought to determine the current trends of trastuzumab use in China and identify certain factors that may influence usage. Though information regarding the use of trastuzumab in the United States, Europe, and other developed countries is currently available, to date there have been no large-scale population-based surveys in China.
The retrospective, multicenter, cross-sectional study was conducted across 155 hospitals in 29 provinces and cities in China between July 2013 and June 2014. To participate in the study, patients needed to meet the following criteria: at least 18 years of age, had undergone surgery for breast cancer and received adjuvant/neoadjuvant therapy, had been diagnosed as having HER2-positive disease, and had stage I to stage III disease.
A total of 4994 HER2-positive breast cancer patients were enrolled in the study. Of these patients, 4879 received adjuvant therapy, 814 received neoadjuvant therapy, and 724 received both adjuvant and neoadjuvant therapy. Among the total patients enrolled in the study, only 29.8% (n = 1488) were given trastuzumab therapy; 30.5% of patients receiving adjuvant therapy were given trastuzumab, and 18.3% of those receiving neoadjuvant therapy were given trastuzumab.
Researchers found that more than two-thirds of patients with HER2-positive breast cancer in China did not receive HER2-targeted therapy, which is a stark contrast to what is seen in Western Europe and the United States, where it was estimated that, according to a prior study, both nations can supply enough trastuzumab to treat “virtually all patients with HER2-positive breast cancer.”
In addition, the presence or absence of insurance coverage for trastuzumab treatment was the strongest predictor of trastuzumab therapy use in Chinese patients, and patients who had coverage were more likely to be prescribed the therapy than those without. Furthermore, women who had to travel to receive treatment were less likely to receive trastuzumab.
Other factors that affected the use of trastuzumab therapy included lymph node involvement and later tumor stage at diagnosis. Researchers hypothesize that these findings could indicate that a patient is more willing to accept, or the physician is more willing to recommend, trastuzumab therapy when the cancer is more advanced.
The study authors hope that drawing attention to these factors will assist future efforts to standardize trastuzumab for the treatment of breast cancer in China.
Reference
Junjie L, Zhimin S, Binghe X, et al. Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: the Nvwa study. Medicine. 2018;97(21): e10350. doi: 10.1097/MD.0000000000010350.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Bevacizumab Biosimilars Offer Promise for CRC Treatment, Wound Healing, and Cost Savings
February 28th 2024A review emphasizes that bevacizumab biosimilars demonstrate comparable efficacy to the reference product (Avastin) in the treatment of colorectal cancer (CRC) by tackling wound healing concerns in anorectal medicine.